Wat is de prijs voor CohBar, Inc. (CWBR)

Het prijs van CohBar, Inc. (CWBR) is $0.41

Wat is de marktkapitalisatie voor CohBar, Inc. (CWBR)

Marktkapitalisatie voorCohBar, Inc. (CWBR) is $1.08M

CohBar, Inc. (CWBR) Aandelensplitsingen

CohBar Inc. is a clinical-stage biotechnology company dedicated to the discovery and advancement of therapies that leverage mitochondrial biology, known as mitochondria-based therapeutics (MBTs). Their primary objective is to combat chronic conditions and diseases associated with aging. These MBTs are being developed to address a broad spectrum of medical challenges, including non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis (IPF), type 2 diabetes, acute respiratory distress syndrome (ARDS), various cancers, and cardiovascular disorders like Alzheimer's disease. Their flagship clinical asset is CB4211, an innovative, optimized analogue of the MOTS-c mitochondrial-derived peptide. This candidate is currently undergoing Phase Ib evaluation as part of a larger Phase Ia/Ib clinical trial, specifically targeting non-alcoholic steatohepatitis (NASH) and obesity. Beyond their clinical work, CohBar's preclinical portfolio features CB5138 analogs aimed at fibrotic conditions, as well as CB5064 analogs being explored for their potential in treating ARDS linked to COVID-19. Established in 2007, CohBar, Inc. maintains its corporate headquarters in Menlo Park, California.

Jaar	Splitsing	Vermenigvuldiging	Cumulatieve vermenigvuldiging
2022-09-23	1:30	x0.033333333333333	x0.033333333333333

Jaar

Splitsing

Vermenigvuldiging

Cumulatieve vermenigvuldiging

2022-09-23

1:30

x0.033333333333333

Bedrijf	Aantal aandelen splitsingen	Cumulatieve vermenigvuldiging	Land
Vertex Pharmaceuticals Incorporated VRTX.US	1	x2	US
Argenx SE ARGX.US	0	-	NL
Lonza Group AG LONN.SW	0	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	0	-	KR
UCB S.A. UCB.BR	0	-	BE

Bedrijf

Aantal aandelen splitsingen

Cumulatieve vermenigvuldiging

Land